Literature DB >> 23274911

Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression.

Yufang Wang1, Sérgia Velho, Efsevia Vakiani, Shouyong Peng, Adam J Bass, Gerald C Chu, Jessica Gierut, James M Bugni, Channing J Der, Mark Philips, David B Solit, Kevin M Haigis.   

Abstract

N-RAS is one member of a family of oncoproteins that are commonly mutated in cancer. Activating mutations in NRAS occur in a subset of colorectal cancers, but little is known about how the mutant protein contributes to the onset and progression of the disease. Using genetically engineered mice, we find that mutant N-RAS strongly promotes tumorigenesis in the context of inflammation. The protumorigenic nature of mutant N-RAS is related to its antiapoptotic function, which is mediated by activation of a noncanonical mitogen-activated protein kinase pathway that signals through STAT3. As a result, inhibition of MAP-ERK kinase selectively induces apoptosis in autochthonous colonic tumors expressing mutant N-RAS. The translational significance of this finding is highlighted by our observation that NRAS mutation correlates with a less favorable clinical outcome for patients with colorectal cancer. These data show for the first time the important role that N-RAS plays in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23274911      PMCID: PMC3595397          DOI: 10.1158/2159-8290.CD-12-0198

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  50 in total

Review 1.  GTPase activating proteins: critical regulators of intracellular signaling.

Authors:  Shane Donovan; Kevin M Shannon; Gideon Bollag
Journal:  Biochim Biophys Acta       Date:  2002-03-14

Review 2.  RAS oncogenes: the first 30 years.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

3.  Endogenous c-N-Ras provides a steady-state anti-apoptotic signal.

Authors:  J C Wolfman; A Wolfman
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

4.  Cellular N-Ras promotes cell survival by downregulation of Jun N-terminal protein kinase and p38.

Authors:  Janice C Wolfman; Todd Palmby; Channing J Der; Alan Wolfman
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

5.  Regulation of Fas-mediated apoptosis by N-ras in melanoma.

Authors:  Jean L Urquhart; Sandra J Meech; David G Marr; Yiqun G Shellman; Richard C Duke; David A Norris
Journal:  J Invest Dermatol       Date:  2002-09       Impact factor: 8.551

6.  Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase.

Authors:  Galit Elad-Sfadia; Roni Haklai; Eyal Ballan; Hans-Joachim Gabius; Yoel Kloog
Journal:  J Biol Chem       Date:  2002-07-30       Impact factor: 5.157

7.  Downstream effectors of oncogenic ras in multiple myeloma cells.

Authors:  Liping Hu; Yijiang Shi; Jung-hsin Hsu; Joseph Gera; Brian Van Ness; Alan Lichtenstein
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

Review 8.  Non-redundancy within the RAS oncogene family: insights into mutational disparities in cancer.

Authors:  Ken S Lau; Kevin M Haigis
Journal:  Mol Cells       Date:  2009-09-30       Impact factor: 5.034

9.  Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells.

Authors:  Paula A Croonquist; Michael A Linden; Fangyi Zhao; Brian G Van Ness
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

10.  Direct visualization of Ras proteins in spatially distinct cell surface microdomains.

Authors:  Ian A Prior; Cornelia Muncke; Robert G Parton; John F Hancock
Journal:  J Cell Biol       Date:  2003-01-13       Impact factor: 10.539

View more
  28 in total

1.  Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.

Authors:  Andrea Cercek; Maria Ignez Braghiroli; Joanne F Chou; Jaclyn F Hechtman; Nancy Kemeny; Leonard Saltz; Marinela Capanu; Rona Yaeger
Journal:  Clin Cancer Res       Date:  2017-04-26       Impact factor: 12.531

2.  Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Authors:  George Mulligan; David I Lichter; Alessandra Di Bacco; Stephen J Blakemore; Allison Berger; Erik Koenig; Hugues Bernard; William Trepicchio; Bin Li; Rachel Neuwirth; Nibedita Chattopadhyay; Joseph B Bolen; Andrew J Dorner; Helgi van de Velde; Deborah Ricci; Sundar Jagannath; James R Berenson; Paul G Richardson; Edward A Stadtmauer; Robert Z Orlowski; Sagar Lonial; Kenneth C Anderson; Pieter Sonneveld; Jesús F San Miguel; Dixie-Lee Esseltine; Matthew Schu
Journal:  Blood       Date:  2013-12-11       Impact factor: 22.113

Review 3.  The duality of human oncoproteins: drivers of cancer and congenital disorders.

Authors:  Pau Castel; Katherine A Rauen; Frank McCormick
Journal:  Nat Rev Cancer       Date:  2020-04-27       Impact factor: 60.716

Review 4.  Impact of somatic mutations on patterns of metastasis in colorectal cancer.

Authors:  Marla Lipsyc; Rona Yaeger
Journal:  J Gastrointest Oncol       Date:  2015-12

5.  SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma.

Authors:  Jerzy Lasota; Artur Kowalik; Anna Felisiak-Golabek; Shingo Inaguma; Zeng-Feng Wang; Liliana Pięciak; Sebastian Zięba; Rafał Pęksa; Janusz Kopczynski; Krzysztof Okoń; Piotr Waloszczyk; Stanislaw Gozdz; Wojciech Biernat; Markku Miettinen
Journal:  Arch Pathol Lab Med       Date:  2017-02-28       Impact factor: 5.534

6.  Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.

Authors:  Georgina Wood; Tal Grenader; Stephen Nash; Richard Adams; Richard Kaplan; David Fisher; Tim Maughan; John Bridgewater
Journal:  Anticancer Drugs       Date:  2017-06       Impact factor: 2.248

7.  Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Authors:  Guangyao Kong; Mark Wunderlich; David Yang; Erik A Ranheim; Ken H Young; Jinyong Wang; Yuan-I Chang; Juan Du; Yangang Liu; Sin Ruow Tey; Xinmin Zhang; Mark Juckett; Ryan Mattison; Alisa Damnernsawad; Jingfang Zhang; James C Mulloy; Jing Zhang
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

Review 8.  The Mystery of Rap1 Suppression of Oncogenic Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Mingzhen Zhang; Chung-Jung Tsai; Anna A Sablina
Journal:  Trends Cancer       Date:  2020-03-02

Review 9.  The mystery of oncogenic KRAS: Lessons from studying its wild-type counter part.

Authors:  Yuan-I Chang; Alisa Damnernsawad; Guangyao Kong; Xiaona You; Demin Wang; Jing Zhang
Journal:  Small GTPases       Date:  2016-07-22

10.  Network analysis of differential Ras isoform mutation effects on intestinal epithelial responses to TNF-α.

Authors:  Ken S Lau; Sarah B Schrier; Jessica Gierut; Jesse Lyons; Douglas A Lauffenburger; Kevin M Haigis
Journal:  Integr Biol (Camb)       Date:  2013-10-02       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.